Neuroendocrine peptide hormone regulation of immunity

Chemical Immunology

Volumn 69, Issue , 1997, Pages 155-184

  Torres, Barbara A ^a   Johnson, Howard M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; ENDORPHIN; ENKEPHALIN; GROWTH HORMONE; LYMPHOKINE; NEUROPEPTIDE; PEPTIDE HORMONE; PROENKEPHALIN; PROLACTIN; PROOPIOMELANOCORTIN; SOMATOSTATIN; SUBSTANCE P; THYROTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIBODY PRODUCTION; HYPERSENSITIVITY; IMMUNE SYSTEM; IMMUNITY; IMMUNOREGULATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; LYMPHOID ORGAN; NEUROENDOCRINE SYSTEM; NEUROIMMUNOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0030690009     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058657     Document Type: Review

References (187)

1. Blalock JE: Peptide hormones shared by the neuroendocrine and immunologie systems. J Immunol 1985;135:858s-861s.
2. Smith EM, Galin S, LeBoeuf RD, Coppenhaver DH, Harbour DV, Blalock JE: Nucleotide and amino acid sequence of lymphocyte-derived corticotropin: Endotoxin induction of a truncated peptide. Proc Natl Acad Sci USA 1990;87:1057-1060.
3. Douglas J, Civelli O, Herbert E: Polyprotein gene expression: Generation of diversity of neuroendocrine peptides. Annu Rev Biochem 1984;53:665-715.
4. Blalock JE, Smith EM: Human leukocyte interferon: Structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci USA 1981;77:5972-5974.
5. Smith EM, Blalock JE: Human lymphocyte production of cotricotropin- and endorphin-like substances: Association with leukocyte interferon. Proc Natl Acad Sci USA 1981;78:7530-7534.
6. Johnson HM, Smith EM, Torres BA, Blalock JE: Regulation of the in vitro antibody response by neuroendocrine hormones. Proc Natl Acad Sci USA 1982;79:4171-4174.
7. Mishell RI, Dutton RW: Immunization of dissociated spleen cell cultures from normal mice. J Exp Med 1976;126:423-442.
8. Mosier DE, Scher I, Paul WE: In vitro responses of CBA/N mice: Spleen cells of mice with an X-linked defect that precludes immune responses to several thymus-independent antigens can respond to TNP-lipopolysaccharide. J Immunol 1976;117:1363-1369.
9. Clarke BL, Bost KL: Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J Immunol 1989;143:464-469.
10. Alvarez-Mon M, Kehrl JH, Fauci AS: A potential role for adrenocorticotropin in regulating B lymphocyte functions. J Immunol 1985;135:3823-3826.
11. Aebischer I, Stampfli MR, Miescher S, Horn M, Zurcher AW, Stadler BM: Neuropeptides accentuate interleukin 4-induced human immunoglobulin E synthesis in vitro. Exp Dermatol 1996;5:38-44.
12. Munn NA, Lum LG: Immunoregulatory effects of α-endorphin, β-endorphin, methionine-enkephalin, and adrenocorticotropic hormone on anti-tetanus toxoid antibody synthesis by human lymphocytes. Clin Immunol Immunopathol 1989;52:376-385.
13. Carr DJJ, Radulescu RT, DeCosta BR, Rice KC, Blalock JE: Differential effect of opioids on immunoglobulin production by lymphocytes isolated from Peyer's patches and spleen. Life Sci 1990; 47:1059-1069.
14. Johnson HM, Torres BA, Smith EM, Dion LD, Blalock JE: Regulation of lymphokine (γ-interferon) production by corticotropin. J Immunol 1984;132:246-250.
15. Epstein LB, Cline MJ, Merigan TC: The interaction of human macrophages and lymphocytes in the phytohemmaglutinin-stimulated production of interferon. J Clin Invest 1971;50:744-753.
16. Torres BA, Farrar WL, Johnson HM: Interleukin-2 regulates immune interferon (IFNγ) production by normal and suppressor cell cultures. J Immunol 1982;128:2217-2219.
17. Torres BA, Yamamoto JK, Johnson HM: Cellular regulation of gamma interferon production: Lyt phenotype of the suppressor cell. Infect Immun 1982;35:770-776.
18. Wybran J, Appelboom T, Famaey J-P, Govaerts A: Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol 1979;123:1068-1070.
19. Hazum E, Chang K-J, Cuatrecasas P: Specific nonopiate receptors for β-endorphin. Science 1979; 205:1033-1035.
20. Gilmore W, Weiner LP: β-Endorphin enhances interleukin 2 (IL 2) production in murine lymphocytes. J Neuroimmunol 1988;18:125-138.
21. Heijnen C, Bevers C, Kavelaars A, Ballieux RE: Effect of 3-endorphin on the antigen-induced primary antibody response of human blood B cells in vitro. J Immunol 1986;136:213-216.
22. 2]β-endorphin with opiate receptors. J Biol Chem 1979;221:309-323.
23. Udenfriend S, Kilpatrick DL: Biochemistry of the enkephalins and enkephalin-containing peptides. Archs Biochem Biophys 1983;221:309-323.
24. Morgan EL, McClurg MR, Janda JA: Suppression of human B lymphocyte activation by β-endorphin. J Neuroimmunol 1990;28:209-217.
25. Williamson SA, Knight RA, Lightman SL, Hobbs JR: Effects of beta-endorphin on specific immune responses in man. Immunology 1988;65:47-51.
26. Rowland RR, Tokuda S: Dual immunomodulation by met-enkephalin. Brain Behav Immun 1989; 3:171-174.
27. Morgan EL: Regulation of human B lymphocytes activation by opioid peptide hormones: Inhibition of IgG production by opioid receptor class (mu-, kappa-, and delta-) selective agonists. J Neuroimmunol 1996;65:21-30.
28. Sizemore RC, Dienglewicz RL, Pecunia E, Gottlieb AA: Modulation of concanavalin A-induced, antigen-nonspecific regulatory cell activity by leu-enkephalin and related peptides. Clin Immunol Immunopathol 1991;60:310-318.
29. Shavit Y, Lewis JW, Terman GW, Gale RP, Liebeskind JC: Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 1984;223:188-190.
30. Flores CM, Hernandez MC, Hargreaves KM, Bayer BM: Restraint stress-induced elevation in plasma corticosterone and β-endorphin are not accompanied by alterations in immune function. J Neuroimmunol 1990;28:219-225.
31. Mathews PM, Froelich CJ, Sibbitt WL, Bankhurst AD: Enhancement of natural cytotoxicity by β-endorphin. J Immunol 1983;13:1658-1662.
32. Kay N, Morley JE, Allen JI: Interaction between endogenous opioid and IL-2 on PHA-stimulated human lymphocytes. Immunology 1990;70:485-491.
33. Faith RE, Liang HJ, Murgo AJ, Plotnikoff NP: Neuroimmunomodulation with enkephalins: Enhancement of human natural killer (NK) cell activity in vitro. Clin Immunol Immunopathol 1984;31:412-418.
34. Foster JS, Moore RN: Dynorphin and related opioid peptides enhance tumoricidal activity mediated by murine peritoneal macrophages. J Leukocyte Biol 1987;42:171-174.
35. Oleson DR, Johnson DR: Regulation of human natural cytotoxicity by enkephalins and selective opiate agonists. Brain Behav Immun 1988;2:171-186.
36. Carr DJJ, DeCosta BR, Jacobson AE, Rice KC, Blalock JE: Cotricotropin-releasing hormone augments natural killer cell activity through a naloxone-sensitive pathway. J Neuroimmunol 1990; 28:53-61.
37. Gilman SC, Schwartz JM, Milner RJ, Bloom FE, Feldman JD: β-Endorphin enhances lymphocyte proliferative responses. Proc Natl Acad Sci USA 1982;79:4226-4230.
38. McCain HW, Lamster IB, Bozzone JM, Grbic JT: β-Endorphin modulates human immunity via non-opiate receptor mechanisms. Life Sci 1982;31:1619-1624.
39. Glimore W, Moloney M, Bernstein T: The enhancement of polyclonal T cell proliferation by beta-endorphin. Brain Res Bull 1990;24:687-692.
40. Hemmick L, Bidlack JM: β-Endorphin stimulates rat T lymphocyte proliferation. J Neuroimmunol 1990;29:239-248.
41. Miller GC, Murgo AJ, Plotnikotf NP: Enhancement of active T-cell rosettes from lymphoma patients. Clin Immunol Immunopathol 1983;26:446-451.
42. Van Epps DE, Saland L: β-Endorphin and [Met]-cnkephalin stimulate human peripheral blood mononuclear cell chemotaxis. J Immunol 1984;132:3046-3053.
43. Ruff M, Schiffmann E, Terranova V, Pert CB: Neuropeptides are chemoattractants for human tumor cells and monocytes: A possible mechanism for metastasis. Clin Immunol Immunopathol 1985;37:387-396.
44. Brown SL, Van Epps DE: Suppression of T lymphocyte chemotactic factor production by the opioid peptides β-endorphin and [Met]-enkephalin. J Immunol 1985;134:3384-3390.
45. Peterson PK, Sharp B, Gekker G, Brummitt C, Keane WF: Opioid-mediated suppression of interferon-γ production by cultured peripheral blood mononuclear cells. J Clin Invest 1987;80:824-831.
46. Morgano A, Setti M, Poerri I, Barabine A, Lotti G, Indiveri F: Expression of HLA-class II antigens and proliferative capacity in autologous mixed lymphocyte reactions of human T lymphocytes exposed in vitro to α-endorphin. Brain Behav Immun 1989;3:214-222.
47. Brownstein MJ, Russell JT, Gainer H: Synthesis, transport, and release of posterior pituitary hormones. Science 1980;207:373-378.
48. Sawyer WH: Neurohypophyseal hormones. Pharmacol Rev 1961;13:225-277.
49. Rossi NF, Schier RW: Role of arginine vasopressin in regulation of systemic arterial pressure. Annu Rev Med 1986;37:13-20.
50. Gibbs DM: Vasopressin and oxytocin: Hypothalamic modulations of the stress response: A review. Psychoneuroendocrinology 1986;11:131-140.
51. Doris PA: Vasopressin and central integrative processes. Neuroendocrinology 1984;38:75-85.
52. Clements JA, Funder JW: Arginine vasopressin (AVP) and AVP-like immune reactivity in peripheral tissues. Endocr Rev 1986;7:449-460.
53. Jessop DS, Murphy D, Larsen PJ: Thymic vasopressin (AVP) transgene expression in rats: A model for the study of thymic AVP hyper-expression in T cell differentiation. J Neuroimmunol 1995;62: 85-90.
54. Jessop DS, Chowdrey HS, Lightman SL, Larsen PJ: Vasopressin is located within lymphocytes in the rat spleen. J Neuroimmunol 1995;56:219-223.
55. Geenen V, Benhida A, Kecha O, Achour I, Vandermissen E, Vanneste Y, Goxe B, Martens H: Development and evolutionary aspects of thymic T cell education to neuroendocrine self. Acta Haematol 1996;95:263-267.
56. Geenen V, Martens H, Vandermissen E, Kecha O, Benhida A, Cormann-Goffin N, Lefebvre PJ, Franchimont P: Thymic neuroendocrine self peptides and T cell selection. Adv Exp Med Biol 1994; 355:21-26.
57. Robert FR, Martens H, Cormann N, Benhida A, Schoenen J, Geenen V: The recognition of hypothalamo-neurohypophyseal functions by developing T cell. Dev Immunol 1992;2:131-140.
58. Robert F, Geenen V: Thymic neuropeptides and T lymphocyte development. Ann NY Acad Sci 1992;650:99-104.
59. Johnson HM, Farrar WL, Torres BA: Vasopressin replacement of interleukin-2 requirement in gamma interferon production: Lymphokine activity of a neuroendocrine hormone. J Immunol 1982; 129:963-986.
60. Johnson HM, Torres BA: Regulation of lymphokine production by arginine vasopressin and oxytocin: Modulation of lymphocyte function by neurohypophyseal hormones. J Immunol 1985;135: 773s-775s.
61. Manning M, Olma A, Klis W, Kolodziejczyk A, Nawrocka E, Misicka A, Seto J, Sawyer WH: Carboxy terminus of vasopressin required for activity but not binding. Nature 1984;308:652-653.
62. Torres BA, Johnson HM: Arginine vasopressin (AVP) replacement of helper cell requirement in IFNγ production: Evidence for a novel AVP receptor on mouse lymphocytes. J Immunol 1988;140: 2179-2183.
63. 125I]-arginine vasopressin binding sites on human peripheral blood mononuclear cells. Life Sci 1993;52:95-105.
64. Teppermann J, Teppermann HM: Metabolic and Endocrine Physiology, ed 5. Chicago, Year Book, 1987, p 131-132.
65. Contagliola S, Madec A-M, Benkirane MM, Orgiazzi J, Carayon P: Monoclonal antibody approach to the relationship between immunological structure and biological activity of thyrotropin. Mol Endocrinol 1988;2:613-618.
66. Pierpaoli W: Psychoneuroimmunology. New York, Academic Press, 1981, pp 575-606.
67. Smith EM, Phan M, Kruger TE, Coppenhaver D, Blalock JE: Human leukocyte production of immunoreactive thyrotropin. Proc Natl Acad Sci USA 1983;80:6010-6013.
68. Peele ME, Carr FE, Baker JR, Wartofsky L, Burman KD: TSH beta subunit gene expression in human lymphocytes. Am J Med Sci 1993;305:1-7.
69. Harbour DV, Kruger TE, Coppenhaver D, Smith EM, Meyer WJ: Differential expression and regulation of thyrotropin (TSH) in T cell lines. Mol Cell Endocrinol 1989;64:229-241.
70. Coutelier J-P, Kehrl JH, Bellur SS, Kohn LD, Notkins AL, Prabhaker BS: Binding and functional effects of thyroid stimulating hormone on human immune cells. J Clin Immunol 1990;10:204-210.
71. Francis T, Burch HB, Cai WY, Lukes Y, Peele M, Carr FE, Wartofsky L, Burman KD: Lymphocytes express thyrotropin receptor-specific mRNA as detected by the PCR technique. Thyroid 1991;1: 223-228.
72. Blalock JE, Johnson HM, Smith EM, Torres BA: Enhancement of the in vitro antibody response by thyrotropin. Biochem Biophys Res Comm 1984;125:30-34.
73. Kruger TE, Blalock JE: Cellular requirements for thyrotropin enhancement of in vitro antibody production. J Immunol 1986;137:197-200.
74. Provinciali M, DiStefano G, Fabris N: Improvement in the proliferative capacity and natural killer cell activity of murine spleen lymphocytes by thyrotropin. Int J Immunopharmacol 1992;14: 865-870.
75. Harbour-McMenamin D, Smith EM, Blalock JE: Production of immunoreactive chorionic gonadotropin during mixe lymphocyte reactions: A possible mechanism for genetic diversity. Proc Natl Acad Soc JSA 1986;83:6834-6838.
76. Fuchs T, Hammarstrom L, Smith CI, Brundin J: Sex-dependent induction of human suppressor T cells by chorionic gonadotropin. J Reprod Immunol 1982;4:185-190.
77. Ricketts RM, Jones DB: Differential effect of human chorionic gonadotropin on lymphocyte proliferation induced by mitogens. J Reprod Immunol 1985;7:225-232.
78. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology, ed 5. New York, Oxford University Press, 1986, pp 352-393.
79. Pernow B: Substance P. Pharmacol Rev 1983;35:85-141.
80. Payan DG, Brewster DR, Goetzl EJ: Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts. J Immunol 1984;133:3260-3265.
81. Payan DG, McGillis JP, Organist ML: Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P. J Biol Chem 1986;261: 14321-14329.
82. McGillis JP, Mitsuhashi M, Payan DG: Immunomodulation by tachykinin neuropeptides. Ann NY Acad Sci 1990;594:84-95.
83. Organist ML, Harvey J, McGillis JP, Mitsuhashi M, Melera P, Payan DG: Characterization of a monoclonal antibody against the lymphoblast substance P receptor. J Immunol 1987;139:1-5.
84. Foreman J, Jordan C: Histamine release and vascular changes induced by neuropeptides. Agents Actions 1983;13:105-116.
85. Kavelaars A, Jeurissen F, Heijnen CJ: Substance P receptors and signal transduction in leukocytes. Immunomethods 1994;5:41-48.
86. Goetzl EJ, Chernov T, Renold F, Payan DG: Neuropeptide regulation of the expression of immediate hypersensitivity. J Immunol 1985;135:802s-805s.
87. Marasco WA, Showell HJ, Becker EL: Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Commun 1982;99:1065-1072.
88. Bar-Shavit Z, Goldman R, Stabinsky R, Gottlieb P, Fridkin M, Teichberg VI, Blumberg S: Enhancement of phagocytosis: A newly found activity of substance P in its N-terminal tetrapeptide sequence. Biochem Biophys Res Commun 1980;94:1445-1451.
89. Hartung H-P, Wolters K, Toyka KV: Substance P: Binding properties and studies on cellular responses in guinea pig macrophages. J Immunol 1986;136:3856-3863.
90. DeRose V, Robbins RA, Snider RM, Spurzem JR, Thiele GM, Rennard SI, Rubenstein I: Substance P increases neutrophil adhesion to bronchial epithelial cells. J Immunol 1994;152:1339-1346.
91. Payan DG, Brewster DR, Goetzl EJ: Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;13:1613-1615.
92. Stanisz AM, Befus D, Bienenstock J: Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 1986;136:152-156.
93. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ: Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984;74:1532-1539.
94. Ruff MR, Wahl SM, Pert CB: Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985;2(suppl 6):10007-111.
95. Lotz M, Vaughn JH, Carson DA: Effects of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-1221.
96. Nair MP, Schwartz SA: Substance P induces tumor necrosis factor in an ex vivo model system. Cell Immunol 1995;166:286-290.
97. Lotz M, Carson DA, Vaughn JH: Substance P activation of rheumatoid synoviocytes: Neural pathways in pathogenesis of arthritis. Science 1987;235:893-895.
98. Yankner BA, Duffy LK, Kirschner DA: Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides. Science 1990;250:279-282.
99. Mitsuhashi M, Akitaya T, Turk CW, Payan DG: Amyloid β substituent peptides do not interact with the substance P receptor expressed in cultured cells. Mol Brain Res 1991;11:177-180.
100. Costa M, Furness JB: The origins, pathways, and terminations of neurons with VIP-like immunoreactivity in the guinea pig small intestine. Neuroscience 1983;8:665-676.
101. Morel G, Besson J, Rosselin G, Dubois PM: Ultrastructural evidence for endogenous vasoactive intestinal peptide-like immunoreactivity in the pituitary gland. Neuroendocrinology 1982;34:85-89.
102. Weithe E, Reinecke M: Peptidergic innervation of the mammalian sinus nodes: Vasoactive intestinal polypeptide, neurotensin, substance P. Neurosci Let 1981;26:283-288.
103. Barajas L, Sokolski DN, Lechago J: Vasoactive intestinal polypeptide-immunoreactive nerves in the kidney. Neurosci Lett 1983;43:263-269.
104. Bloom SR, Polak JM: Regulatory peptides and the skin. Clin Exp Dermatol 1983;8:3-18.
105. Feiten DL, Feiten SY, Carlson SL, Olschowska JA, Livnat S: Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985;135:755s-765s.
106. Lundberg JM, Pernow AA, Hokfelt T: Neuropeptide Y-, substance P- and VIP-immunoreactive nerves in cat spleen in relation to autonomie vascular and volume control. Cell Tissue Res 1985; 239:9-18.
107. O'Dorisio MS, Wood CL, O'Dorisio TM: Vasoactive intestinal peptide and neuropeptide modulation of the immune response. J Immunol 1985;135:792s-799s.
108. Frawley LS, Neill JD: Stimulation of prolactin secretion in rhesus monkeys by vasoactive intestinal polypeptide. Neuroendocrinology 1981;33:79-83.
109. Feliu JE, Mojena M, Silvestre RA, Monge J, Marco J: Stimulatory effect of vasoactive intestinal peptide on glycogenolysis and gluconeogenesis in isolated rat hepatocytes: Antagonism by insulin. Endocrinology 1983;112:2120-2127.
110. Magisretti PJ, Morrison JH, Shoemaker WJ, Sapin V, Bloom FE: Vasoactive intestinal polypeptide induces glycogenolysis in mouse control of energy metabolism. Proc Natl Acad Sci USA 1981;78: 6535-6539.
111. Epelbaum J, Tapia-Aranciba L, Besson J, Rotszteyn WH, Kordon C: Vasoactive intestinal peptide inhibits release of somatostatin from hypothalamus in vitro. Eur J Pharmacol 1979;58:493-495.
112. 2α; in Said (ed): Vasoactive ntestinal Peptide. New York, Raven Press, 1982, pp 185-192.
113. Ottesen B, Gerstenberg T, Ulrichsen H, Manthrope T, Fahrenkrug J, Wagner G: Vasoactive intestinal polypeptide (VIP) increases vaginal blood flow and inhibits uterine smooth muscle activity in women. Eur J Clin Invest 1983;13:321-324.
114. O'Dorisio MS, O'Dorisio TM, Cataland S, Balcerzak SP: VIP as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med 1980;96:666-672.
115. Cutz E, Chan W, Track NS, Goth A, Said S: Release of vasoactive intestinal polypeptide in mast cells by histamine liberatore. Nature 1978;275:661-662.
116. Leceta J, Martinez MC, Delgado M, Garrido E, Gomariz RP: Lymphoid cell populations containing vasoactive intestinal peptide in the rat. Peptides 1994;15:791-797.
117. Gomariz RP, Leceta J, Garrido E, Garrido T, Delgado M: Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul Pept 1994;50:177-184.
118. Goetzl EJ, Sreedham SP, Turck CW: Structurally distinctive vasoactive intestinal peptides from rat basophilic leukemia cells. J Biol Chem 1988;263:9083-9086.
119. Ottaway CA, Greenburg GR: Interaction of vasoactive intestinal peptide with mouse lymphocytes: Specific binding and the modulation of mitogen responses. J Immunol 1984;132:417-423.
120. Ottaway CA, Bernaerts C, Chan B, Greenberg GR: Specific binding of VIP to human circulating mononuclear cells. Can J Physiol Pharmacol 1983;61:664-671.
121. Ottaway CA: Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 1987;62:291-297.
122. Ganea D, Sun L: Vasoactive intestinal peptide downregulates the expression of IL 2 but not of IFN gamma from stimulated murine T lymphocytes. J Neuroimmunol 1993;47:147-158.
123. Sun L, Ganea D: Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol 1993;48:59-69.
124. Wang HY, Xin Z, Tang H, Ganea D: Vasoactive intestinal peptide inhibits IL 4 production in myrine T cells by a post-transcriptional mechamism. J Immunol 1996;156:3243-3253.
125. Martinez C, Delgado M, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL 10 production in murine T lymphocytes. J Immunol 1996;156:4128-4136.
126. Hassner A, Lau MS, Goetzl EJ, Adelman DC: Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide. J Allergy Clin Immunol 1993;92:891-901.
127. Elson CO, Heck JA, Strober W: T-cell regulation of murine IgA synthesis. J Exp Med 1979;149: 632-643.
128. Richman LK, Graeff AS, Yarchoan R, Strober W: Simultaneous induction of antigen-specific IgA helper T cell and IgG suppressor T cells in the murine Peyer's patch after protein feeding. J Immunol 1981;126:2079-2083.
129. Rola-Pleszcynski M, Bolduc D, St Pierre S: The effects of vasoactive intestinal peptide on human natural killer function. J Immunol 1985;135:2569-2573.
130. Sirianni MC, Annibale B, Tagliaferri F, Fais S, DeLuca S, Pallone F, DelleFave G, Aiuti F: Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family: VIP, glucagon, and GHRF specifically inhibit NK activity. Regul Pept 1992;38:79-87.
131. Hoist JJ, Fahrenkrug J, Jensen SL, Nielsen OU: Peptidergic innervation of the pancreas; in Bloom SR, Polak JM (eds): Gut Hormones. Edinburgh. Churchill-Livingstone, 1981, pp 495-511.
132. Koff WC, Dunegan MA: Modulation of macrophage-mediated tumoricidal activity by neuropeptides and neurohormones. J Immunol 1985;135:350-354.
133. Yiangou Y, Serrano R, Bloom SR, Pena J, Festenstein H: Effects of preprovasoactive intestinal peptide-derived peptides on the murine immune response. J Neuroimmunol 1990;29:65-72.
134. Moore TC: Modification of lymphocyte traffic by vasoactive neurotransmitter substances. Immunology 1984;52:511-518.
135. Ottaway CA: In vitro alteration of receptors for vasoactive intestinal peptide changes in vivo localization of mouse T cells. J Exp Med 1984;160:1054-1069.
136. O'Dorisio MS, Hermina NS, O'Dorisio TM, Balcerzak SP: Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase. J Immunol 1981;127:2551-2554.
137. Gomariz RP, Garrido E, Leceta J, Martinez C, Abalo R, Delgado M: Gene expression of VIP receptor in rat lymphocytes. Biochem Biophys Res Commun 1994;203:1599-1604.
138. Beed EA, O'Dorsio MS, O'Dorsio TM, Gaginella TS: Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt-4B lymphoblasts. Regul Pept 1983;6:1-12.
139. Svoboda M, Tastenoy M, Van Rampelbergh J, Goosens JF, DeNeef P, Waelbroeck M, Robberecht P: Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994;205:1617-1624.
140. Cheng PP, Sreedharan SP, Kishiyama JL, Goetzl EJ: The SKW6.4 line of human B lymphocytes specifically binds and responds to vasoactive intestinal peptide. Immunology 1993;79:64-68.
141. O'Dorsio MS: Biochemical characteristics of receptors for vasoactive intestinal polypeptide in nervous, endocrine, and immune systems. Fed Proc 1987;46:192-195.
142. Ottaway GA, Lay TE, Greenberg GR: High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes. J Neuroimmunol 1990;29: 149-155.
143. O'Dorisio MS, Wood CL, Wenger GD, Vassallo LM: Cyclic AMP-dependent protein kinase in Molt-4B lymphoblasts: Identification by photoaffinity labeling and activation in intact cells by the neuropeptides vasoactive intestinal polypeptide and peptide histidine isoleucine. J Immunol 1985; 134:4078-4086.
144. Gilman AG: G proteins and dual control of adenylate cyclase. Cell 1984;36:577-579.
145. Laycock JF, Wise PH: The hypothalamo-hypophyseal system: in Laycock JF: Essential Endocrinology, ed 2. New York, Oxford University Press, 1983, pp 29-76.
146. Rudman D: Growth hormone, body composition, and aging. J Am Geriatr Soc 1985;33:800-807.
147. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
148. Weigent DA, Baxter JB, Wear WE, Smith LR, Bost KL, Blalock JE: Production of immunoreactive growth hormone by mononuclear leukocytes. FASEB J 1988;2:2812-2818.
149. Hattori N, Shimatsu A, Sugita M, Kumagi S, Imura H: Immunoreactive growth hormone (GH) secretion by human lymphocytes: Augmented release by exogenous GH. Biochem Biophys Res Commun 1990;168:396-401.
150. Hiestand PC, Mekler P, Nordmann R, Grieder A, Permmongkol C: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA 1986;83:2599-2603.
151. Smith PE: The effect of hypophysectomy upon the involution of the thymus in the rat. Anat Rec 1930;47:119-129.
152. Berczi I, Nagy E: A possible role of prolactin in adjuvant arthritis. Arthritis Rheum 1982;25: 591-594.
153. Nagy E, Berczi I, Friesen HG: Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 1983;102:351-357.
154. Arranbrecht S: Specific binding of growth hormone to thymocytes. Nature 1974;252:255-257.
155. 125I-human growth hormone to specific receptors in human cultured lymphocytes. J Biol Chem 1974;249:1661-1667.
156. Kiess W, Butenandt O: Specific growth hormone receptors on human peripheral mononuclear cells: Reexpression, identification, and characterization. J Clin Endocrinol Metab 1985;60:740-746.
157. Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE: Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporine. J Immunol 1985; 134:3027-3031.
158. Russell DH, Matrisian L, Kibler R, Larson DF, Poulos B, Magun BD: Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Biochem Biophys Res Commun 1984; 121:899-906.
159. 3 pituitary adenoma cells can reverse thymic aging rats. Proc Natl Acad Sci USA 1986;83:5663-5667.
160. Prysor-Jones RA, Jenkins JS: Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle. J Endocrinol 1980;85:75-82.
161. Seo H, RefetoffS, Fang VS: Induction of hypothyroidism and hypoprolactinemia by growth hormone producting rat pituitary tumors. Endocrinology 1977;100:216-226.
162. Davila DR, Brief S, Simon J, Hammer RE, Brinster RL, Kelley KW: Role of growth hormone in regulating T-dependent immune events in aged, nude, and transgenic rodents. J Neurosci Res 1987; 18:108-116.
163. Kelley KW: The role of growth hormone in modulation of the immune response. Ann NY Acad Sci 1990;594:95-103.
164. Weigent DA, Blalock JE, LeBouef RD: An antisense oligodeoxynucleotide to growth hormone messenger ribonucleic acid inhibits proliferation. Endocrinology 1991;128:2053-2057.
165. Nicoll CS, Bern HA: On the actions of prolactin among the vertebrates: Is there a common denominator? In Wolstenholme GEW, Knight J (eds): Lactogenic Hormones. London, Churchill-Livingstone, 1972, pp 299-317.
166. Bernton EW, Meltzer MS, Holaday JW: Suppression of macrophage activation and T lymphocyte function in hypoprolactinemic mice. Science 1988;239:401-404.
167. Wilner ML, Ettenger RB, Koyle MA, Rosenthal JY: The effect of hypoprolactinemia alone and in combination with cyclosporine on allograft rejection. Transplantation 1990;49:264-267.
168. Carrier M, Russell DH, Wild JC, Emery RW, Copeland JG: Prolactin as a marker of rejection in human heart transplantation. J Heart Transplant 1987;6:290-292.
169. Berczi I, Nagy E, DeToledo SM, Matusik RJ, Friesen HG: Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue. J Immunol 1991;146:2201-2206.
170. Russell DH: New aspects of prolactin and immunity: A lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 1989;10:40-44.
171. Tabor CW, Tabor H: Polyamines. Annu Rev Biochem 1984;53:749-790.
172. Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB: Regulation in interleukin-2-driven T lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA 1990;87:6460-6464.
173. Turkington RW: Ectopic production of prolactin. N Engl J Med 1971;285:1455-1458.
174. Rosen SW, Weintraub BD, Aaronson SA: Nonrandom ectopic protein production by malignant cells: Direct evidence in vitro. J Clin Endocrinol Metab 1980;50:834-841.
175. DiMattia GE, Gellersen B, Bohnet HG, Friesen HG: A human B lymphoblastoid cell line produces prolactin. Endocrinology 1988;122:2508-2517.
176. Montgomery DW, Zukoski CF, Shah GN, Buckley AR, Pacholczyk T, Russell DH: Concanavalin A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity and immunoreactivity. Biochem Biophys Res Commun 1987;145:692-698.
177. Schuller LA, Hurley WL: Molecular cloning of a prolactin-related mRNA expressed in bovine placenta. Proc Natl Acad Sci USA 1987;84:5650-5654.
178. Duckworth ML, Kirk KL, Friesen HG: Isolation and identification of a cDNA clone of rat placental lactogen. J Biol Chem 1986;261:10871-10878.
179. Linzer DIH, Lee S-J, Ogren L, Talamantes F, Nathans D: Identification of proliferin mRNA and protein in mouse placenta. Proc Natl Acad Sci USA 1985;82:4356-4359.
180. Payan DG, Hess CA, Goetzl EJ: Inhibition by somatostatin of the proliferation of T lymphocytes and Molt-4 lymphoblasts. Cell Immunol 1984;84:433-438.
181. Malec P, Zeman K, Markiewicz K, Tchorzewski H, Nowak Z, Baj Z: Short-term somatostatin infusion affects T lymphocyte responsiveness in humans. Immunopharmacology 1989;17:45-49.
182. Muscettola M, Grasso G: Somatostatin and vasoactive intestinal peptide reduce interferon-gamma production by peripheral blood mononuclear cells. Immunobiology 1990;180:419-430.
183. Wagner M, Hengst K, Zierden E, Gerllach U: Investigations of the antiproliferative effect of somatostatin in man and rats. Metab Clin Exp 1979;27:1381-1386.
184. Hinterberger W, Cerny C, Kinast M, Pointer H, Trag KM: Somatostatin reduces the release of colony-stimulating activity (CSA) from PHA-activated mouse spleen lymphocytes. Experientia 1977; 34:860-862.
185. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ: Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;62:655-658.
186. Nakamura H, Koike T, Hiruma K, Sate T, Tomioka H, Yoshida S: Identification of lymphoid cell lines bearing receptors for somatostatin. Immunology 1987;62:655-658.
187. Pawlikowski M, Stepien M, Kunert-Radek J, Zelazowski P, Schally AV: Immunomodulatory action of somatostatin. Ann NY Acad Sci 1987;496:233-239.